ADAPT Act

The ADAPT Act, S2356, was introduced in the Senate on July 17, 2025, and subsequently referred to the Committee on Finance. This bill seeks to expand coverage for psychological services under Medicare, Medicaid, and CHIP when those services are provided by supervised advanced psychology trainees. A companion bill, HR4484, has been introduced in the House, indicating a coordinated legislative effort. The bill does not specify a direct funding amount but rather expands the scope of services eligible for reimbursement under existing federal healthcare programs. This means that while no new appropriations are authorized by this bill, it broadens the types of services that can be billed to Medicare, Medicaid, and CHIP. The mechanism is through amending the Social Security Act to include services furnished by advanced psychology trainees under the general supervision of a clinical psychologist. Healthcare insurers such as UnitedHealth Group ($UNH), Humana Inc. ($HUM), and CVS Health Corporation ($CVS) are structurally positioned to benefit from this legislation. By expanding the types of mental health services covered, the bill could lead to increased utilization of psychological services, which would translate into higher claims processing and potentially increased premium revenues for these insurers. Diagnostic service providers like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) are less directly impacted by this specific bill, as it focuses on psychological services rather than laboratory diagnostics. Looking at recent market data, UnitedHealth Group ($UNH) is currently at $281.36, showing a +7.48% increase over the last 7 days but a -2.57% decrease over the last 30 days. Humana Inc. ($HUM) is at $182.65, with a +10.03% increase over 7 days and a +1.05% increase over 30 days. CVS Health Corporation ($CVS) is at $73.28, up +4.48% over 7 days but down -6.88% over 30 days. These recent movements reflect broader market dynamics and are not directly attributable to the ADAPT Act, which is still in its early legislative phase. The bill's effective date for services would be one year after enactment, meaning any market impact would be delayed. As of April 7, 2026, the ADAPT Act (S2356) remains in the early stages of the legislative process, having been referred to the Senate Committee on Finance. The next steps would involve committee consideration, potential hearings, and a committee vote before it could move to the full Senate for a vote. The existence of a companion bill (HR4484) suggests bipartisan and bicameral interest, which could increase its chances of eventual passage, but the timeline for such action is uncertain.